D.E. Shaw & Co
DNTH icon

D.E. Shaw & Co’s Dianthus Therapeutics DNTH Stock Holding History

D.E. Shaw & Co’s Portfolio DNTH Stock Details DNTH Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$12.6M Sell
149,609
-5,069
-3% -$294K 0.01% 1453
2025
Q4 		$6.37M Buy
154,678
+123,064
+389% +$4.77M ﹤0.01% 2108
2025
Q3 		$1.24M Buy
+31,614
New +$808K ﹤0.01% 3322
2022
Q3 		– Sell
-3,314
Closed -$64K – 5260
2022
Q2 		$64K Buy
3,314
+2,190
+195% +$54.1K ﹤0.01% 4803
2022
Q1 		$52K Buy
+1,124
New +$61.4K ﹤0.01% 5135
2018
Q4 		– Sell
-1,116
Closed -$214K – 3799
2018
Q3 		$214K Buy
+1,116
New +$235K ﹤0.01% 3516

Other funds holding DNTH

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
APM
Avidity Partners Management Dallas, Texas $936M AUM 195% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
RCM
RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
FFM
Fairmount Funds Management West Conshohocken, Pennsylvania $1.38B AUM 407.79% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
OCA
Octagon Capital Advisors New York $904M AUM 737.04% 1-Year Est. Return
TCM
TCG Crossover Management Palo Alto, California $3.5B AUM 1,165.83% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return

D.E. Shaw & Co's DNTH Position: Q1 2026 in Review

D.E. Shaw & Co reduced its Dianthus Therapeutics (DNTH) stake by 3.3% in Q1 2026, selling an estimated $294K and leaving 149,609 shares worth $12.6M. The position accounts for 0.01% of the portfolio, ranked #1453.

D.E. Shaw & Co first reported a position in DNTH in Q3 2018 and has held it in 6 quarters since. 241 funds tracked by Wall St. Rank hold DNTH as of Q1 2026.

  • D.E. Shaw & Co held 149,609 shares of Dianthus Therapeutics worth $12.6M as of Q1 2026.
  • D.E. Shaw & Co sold 5,069 Dianthus Therapeutics shares in Q1 2026, an estimated $294K.
  • Dianthus Therapeutics made up 0.01% of D.E. Shaw & Co's portfolio in Q1 2026, its #1453 holding.
  • D.E. Shaw & Co first reported a position in Dianthus Therapeutics in Q3 2018 and has held it in 6 quarters since.
  • 241 funds tracked by Wall St. Rank held Dianthus Therapeutics as of Q1 2026.

Based on D.E. Shaw & Co's 13F filing for Q1 2026, filed 15 May 2026.